Vimarsana
Biggest News Aggregation in the World

Massachusetts Based Neumora News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Massachusetts Based Neumora. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Massachusetts Based Neumora Today - Breaking & Trending Today

RayzeBio, Neumora Perk Up the IPO Market, Raising $561M for Clinical Trials - Vimarsana News

RayzeBio, Neumora Perk Up the IPO Market, Raising $561M for Clinical Trials

RayzeBio’s IPO will support pivotal testing of a targeted radiopharmaceutical for cancer patients who progress after treatment with Novartis’s Lutathera. Neumora will apply its IPO cash toward Phase 3 testing of a depression drug with a novel mechanism of action.

SoftBank-backed Neumora Therapeutics aims to raise up to $264.8 million in US IPO - Vimarsana News

SoftBank-backed Neumora Therapeutics aims to raise up to $264.8 million in US IPO

-Biopharmaceutical firm Neumora Therapeutics, backed by Amgen and Japan's SoftBank, is aiming to raise up to $264.8 million in its U.S. initial public offering, according to a regulatory filing on... -Today at 06:29 am- MarketScreener

SoftBank-backed Neumora Therapeutics aims to raise up to $264.8 mln in US IPO - Vimarsana News

SoftBank-backed Neumora Therapeutics aims to raise up to $264.8 mln in US IPO

Biopharmaceutical firm Neumora Therapeutics, backed by Amgen and Japan's SoftBank , is aiming to raise up to $264.8 million in its U.S. initial public offering, according to a regulatory filing...

SoftBank-backed Neumora Therapeutics aims to raise up to $265m in US IPO - Vimarsana News

SoftBank-backed Neumora Therapeutics aims to raise up to $265m in US IPO

Biopharmaceutical firm Neumora Therapeutics, backed by Amgen and Japan's SoftBank, is aiming to raise up to $264.8 million in its US IPO.

 - Vimarsana News

(Reuters) -- Neumora Therapeutics, backed by Amgen and Japan's SoftBank, is seeking a valuation of up to $2.74 billion in its U.S. initial public offe

Source: nikkei.com